Poxel Aktie [WKN DE: A14M04 / ISIN: FR0012432516]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Poxel SA

22.06.22		Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting (Businesswire)
09.06.22		Poxel Announces New Solid Form Patent for PXL065 that Provides Additional Protection through 2041 (Businesswire)
31.05.22		Poxel Announces its Participation in Upcoming Investor and Scientific Conferences (Businesswire)
17.05.22		Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2022 (Businesswire)
17.05.22		Poxel Announces PXL065 and PXL770 Granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy (Businesswire)
13.05.22		Poxel Announces Notice of Its Annual General Meeting to Be Held on June 21, 2022 (Businesswire)
04.05.22		Poxel Announces Availability of Its 2021 Universal Registration Document (Businesswire)
25.04.22		Poxel Announces Its Participation in Upcoming Scientific Conferences (Businesswire)
11.04.22		Poxel Announces PXL770 Awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy (Businesswire)
22.03.22		Poxel Reports Financial Results for Full Year 2021 and Provides Corporate Update (Businesswire)
15.03.22		Poxel to Report Financial Results for Full Year 2021 and Host Webcast Call on March 22, 2022 (Businesswire)
16.02.22		Poxel Reports Financial Update for Cash and Revenue for the Full Year 2021 and Provides Corporate Update (Businesswire)
16.02.22		Poxel Announces PXL065 Granted FDA Fast Track Designation for X-linked Adrenoleukodystrophy (Businesswire)
04.01.22		Poxel Announces Financial Calendar for 2022 (Businesswire)
25.06.21		Poxel Presents Results of Two Clinical Studies on its Direct AMP Kinase Activator, the PXL770, at the International Liver Congress (ILC)™ 2021 (Businesswire)
24.06.21		Poxel Announces Results from June 23, 2021 Ordinary Annual and Extraordinary General Meeting (Businesswire)
23.06.21		Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan (Businesswire)
19.05.21		Poxel Announces Participation at Upcoming Virtual Investor Conferences in June (Businesswire)
19.05.21		Poxel Announces Notice of its Annual General Meeting to be Held on June 23, 2021 (Businesswire)
11.05.21		Poxel Announces its Participation at the 64th Annual Meeting of the Japan Diabetes Society (Businesswire)
29.04.21		Poxel Announces its Participation at the Mitochondria-Targeted Drug Development Summit (Businesswire)
21.04.21		Poxel Provides Corporate Update and Reports Cash and Revenue for the First Quarter 2021 (Businesswire)
24.03.21		Poxel Reports Financial Results for Full Year 2020 and Provides Corporate Update (Businesswire)
12.02.21		Poxel Reports Financial Update for Cash and Revenue for the Full Year 2020 and Provides Corporate Update (Businesswire)
14.01.21		Poxel Regains Imeglimin Rights From Metavant (Businesswire)
05.01.21		Poxel Announces Financial Calendar for 2021 (Businesswire)
17.12.20		Poxel Announces Participation at Upcoming Virtual Investor Conferences (Businesswire)
30.11.20		Poxel to Host Virtual NASH Investor Event with Leading Experts on December 14, 2020 (Businesswire)
20.11.20		Poxel Provides Update on Metavant Partnership with Imeglimin (Businesswire)
16.11.20		Poxel Presents Phase 1b Clinical Results for PXL065 and New Preclinical Data for PXL770 at AASLD The Liver Meeting® 2020 (Businesswire)
09.11.20		Poxel Announces Upcoming Poster Presentations at AASLD The Liver Meeting® 2020 (Businesswire)
27.10.20		Poxel Announces Participation at Several Upcoming Scientific and Investor Conferences (Businesswire)
20.10.20		Poxel Provides Corporate Update and Reports Cash and Revenue for the Third Quarter and Nine Months 2020 (Businesswire)
15.10.20		Poxel Secures EUR 6 Million in Non-Dilutive Financing Guaranteed by the French Government (Businesswire)
01.10.20		Poxel Announces Positive Results From Phase 2a NASH Trial With PXL770, an Oral First-in-Class Direct AMPK Activator (Businesswire)
24.09.20		Poxel Presents Imeglimin Phase 3 TIMES Results and PXL770 Preclinical Cardio-Renal Results at the 56th European Association for the Study of Diabetes Annual Meeting (Businesswire)
21.09.20		Poxel Announces Participation at Upcoming Scientific and Investor Conferences (Businesswire)
15.09.20		Poxel Reports Financial Results for First Half 2020 and Provides a Corporate Update (Businesswire)
03.09.20		Poxel to Host Conference Call for First Half 2020 Financial Results on September 15, 2020 (Businesswire)
02.09.20		Poxel Initiates Phase 2 NASH Trial for PXL065 (DESTINY 1) in Biopsy-Proven Patients (Businesswire)
30.07.20		Poxel Announces Submission of Imeglimin Japanese New Drug Application for the Treatment of Type 2 Diabetes by Sumitomo Dainippon Pharma (Businesswire)
25.06.20		Poxel Announces Results from June 24, 2020 Ordinary Annual and Extraordinary General Meeting (Businesswire)
24.06.20		Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASH (Businesswire)
25.05.20		Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases (Businesswire)
21.04.20		Poxel Announces First Quarter 2020 Financial and Corporate Update (Businesswire)
20.04.20		Poxel Announces Publication of Imeglimin Clinical Study Results in Clinical Pharmacokinetics (Businesswire)
20.04.20		Poxel Announces Availability of 2019 Universal Registration Document and Provides Business Update (Businesswire)
26.03.20		Poxel Reports Financial Results for Full Year 2019 and Provides Corporate Update (Businesswire)
23.03.20		Poxel to Host Conference Call for Full Year 2019 Financial Results and Provide Corporate Update on March 26, 2020 at 2:30 pm EDT (Businesswire)
04.03.20		Poxel to Report Full Year 2019 Financial Results and Host Conference Call on March 26, 2020 (Businesswire)

Zurück | 1 | 2 | Weiter

Newssuche

Meistgelesene Nachrichten

Solana Kurs Prognose: Jetzt einsteigen und Millionär werden?

Pierer Mobility-Aktie mit zweistelligem Kurssprung: KTM AG wird fortgeführt - Eigenverwaltung bleibt

Bullishe Aussichten: Das erwartet JPMorgan für den Goldpreis in 2025

Mayr-Melnhof startet im kommenden Jahr Aktienrückkauf - Aktie gewinnt deutlich

Lilium-Aktie zündet Kursrakete: Lilium kann neuen Investor von sich überzeugen

Bitcoin Kurs Prognose: BTC verliert 10 Prozent, jetzt schnell verkaufen?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	26.12.2024 17:07
Kaufwert:	EUR
	Hinzufügen Speichern